If you would like to earn credit, you must take the pre-test first by clicking here.

This activity was supported by educational grants from AbbVie Inc. and Pfizer Inc.

Current and Future Directions in PARP Inhibition

Megan E. Grudem, APRN, CNP
Mayo Clinic

Andrea E. Wahner Hendrickson, MD
Mayo Clinic

Review how far PARP inhibition has come and discover where it’s headed, including its potential role in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other factors.


Download Slides


These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.